The PCMA Annual Meeting is the industry’s premier executive conference. The event provides an un-matched and ideal venue for senior executives from PBMs, specialty pharmacy, payer organizations, and pharmaceutical manufacturers to network, conduct business and learn about the most current issues impacting the industry.
The decision makers in attendance, educational insights and business connections made while on-site, are ultimately what make the Annual Meeting so successful. The high level interactions that take place at this event help to promote continued industry collaboration and dialogue.
Conference Program Book
Annual Meeting 2017 Agenda
9:30 am - 9:45 am | Welcome Conference Moderator: Betty Nguyen, Anchor and Journalist, NBC News & MSNBC The Political and Policy Environment of Health Care Mark Merritt, President & Chief Executive Officer, PCMA | |
9:45 am - 10:15 am | Embracing Industry Disruption and Innovation to Improve Patient Care and Outcomes Mostafa Kamal, Chief Executive Officer, Magellan Rx Management View DetailsWe are living in a world where the consumer is key and where industries are rapidly evolving to respond to increased consumer awareness and engagement. Amazon and Uber offer excellent examples of businesses that are booming because of their ability to successfully engage their constituencies and respond to evolving needs and demands. The PBM industry needs to also embrace innovation and disruption and in doing so, can improve patient care and outcomes. During this session, Mostafa will discuss the need for both traditional and new PBM tools to respond to industry challenges and client needs. He will provide examples of industry innovation that embraces disruption, and he will discuss the importance of PBMs and manufacturers working as partners, rather than as adversaries, to effect change around patient care and outcomes. | |
10:15 am – 10:45 am | The Long View from Wall Street: Four Inflection Points Ronny Gal, Senior Analyst, Global Specialty Pharmaceuticals and Biotechnology, Sanford Bernstein View DetailsWall Street analysts always offer a distinctive perspective of our industries. This session will address what Ronny believes to be the current key drivers impacting the U.S. pharmaceutical market. Topics will include:
| |
10:45 am – 11:15 am | How Drug Channel Disruption Will Alter Pharmacy Benefit Management Adam Fein, President, Pembroke Consulting, Inc. & Chief Executive Officer, Drug Channels Institute View DetailsIn this thought-provoking session, you’ll hear from industry expert Dr. Fein as he provides you with his perspective on crucial channel trends affecting pharmacy benefit management. During his presentation, Adam will:
| |
11:15 am – 11:45 am | A Recent Insider’s Assessment of Drug Trend and Marketplace Challenges David Pyott, Professional Director, Private Investor, Philanthropist & Former Chairman of the Board and Chief Executive Officer of Allergan View DetailsAs somewhat of an industry observer since he left Allergan in 2015, David Pyott has the unique opportunity to offer a candid and unbiased assessment of the trends he has seen as shaping the pharma industry over the last three years and how those dynamics are shaping pharma’s interaction with PBMs in the context of a high price drug debate. During this session, David will touch on themes such as:
|
9:00 am – 9:30 am | State of the PBM-Manufacturer Partnership Tim Wentworth, Chief Executive Officer & President, Express Scripts View DetailsAs the other sessions at the conference highlight, a number of challenges and opportunities exist for the future of the prescription drug market. During his session, PCMA’s incoming Chairman of the Board, Tim Wentworth, will offer a strategic perspective with regard to those challenges and opportunities. Tim will offer comments on the state of PBM-manufacturer relations and business objectives. Additionally, he will review changes in the pharmacy marketplace, options for changes to public policy, and a path forward to solve legislative and regulatory issues of interest to both the PBM and pharma industries. | |
9:30 am – 10:15 am | Shared Responsibility for Managing the Overall Cost of Care and Ensuring Patient Access at a Reasonable Cost Burden Troy Brennan, Executive Vice President & Chief Medical Officer, CVS Health Jim Meyers, Executive Vice President, Worldwide Commercial Operations, Gilead Sciences Moderator: Ren Elder, President, Affect Rx, LLC View DetailsPrescription drug cost continues to be an important subject for the PBM and pharma industries. Breakthrough therapies are entering the market and delivering tremendous value to our health care system. But we have to figure out how to pay for them. Every health care industry stakeholder including manufacturers, payers, PBMs, specialty pharmacies, hospitals, 340B entities, etc. has a role to play in managing the overall cost of care in the U.S. healthcare system and in ensuring patient access at a reasonable cost burden. Policymakers are telling all of us that if we can’t figure it out, they will figure it out for us and everyone in the audience can probably all agree that substantive government intervention would not be in the best interest of patient care. During the course of this discussion, the panel will address the following proposed ideas that highlight the need for collaboration in addressing the challenges of drug access and affordability:
| |
10:15 am – 11:00 am | Challenges in Payment and Delivery Systems for a New World of Complex Therapies Jim Clement, Executive Director, Cost of Care and Supply Chain Strategy, Aetna Pharmacy Management John Furey, Chief Operating Officer, Spark Therapeutics Moderator: Tom Knox, President, Fathom Healthcare Solutions, Inc. View DetailsA once just imagined world where complex treatments like gene and CAR T-cell therapies brought new hope to people suffering from life-threatening and life-altering diseases is suddenly here today. These products have the potential to fundamentally change the way we treat disease, but upfront costs and long-term durability of response present pricing and market access challenges. Gene therapy specifically, is an emerging field filled with great discoveries and the potential of creating major medical breakthroughs, including new approaches that may provide long-term, life-altering benefits to patients through the one-time administration of therapy. The health care system will need to evolve to be able to support the availability of these medical breakthroughs. Manufacturers and PBMs are exploring new and unique payment and delivery models to accommodate these new therapies. During this session, the panel will explore the thought processes and steps it takes to navigate these unique arrangements and they will reflect on early lessons learned. The panel will talk about the steps taken and issues considered to get where they are today, why it’s important to start the process early, and the importance for both sides to be willing to consider alternative, innovative solutions to help ensure access to innovative therapies. The discussion will start with a foundation of novel, one-time therapies with key considerations and opportunities, followed by short-term solutions and finally discussing what some of the longer-term solutions may look like. | |
11:00 am – 11:30 am | Delivering Beyond Value Everett Neville, Senior Vice President, Supply Chain and Specialty, Express Scripts View DetailsPatients, payers, and policy makers are demanding value. “Value” seems to be the most recent buzzword used by payers, PBMs, and manufacturers when talking about improving care and lowering prescription drug costs but what does that really mean? PBMs are working with manufacturers to deliver results, including keeping the drug trend lower than the cost of inflation and delivering more than $1.8B in savings in 2017 through the national preferred formulary or other innovative programs, but that’s not enough. Value is not just about trend but it’s about better overall health care and in order to ensure future affordability, we need to look beyond value. During this session Everett will share his views related to value, innovation, technology and the need for continued and deeper collaboration between our industries. | |
11:30 am – 12:00 pm | Trends in Drug Benefit Design Kevin Host, President & Chief Operating Officer, PSG & Artemetrx Solutions View DetailsAs drug costs continue to rise, employers also continue to cite managing their specialty and overall drug benefit cost trend as their number one priority. During this session, Kevin will share the trends coming out of the payer community in terms of how they are structuring pharmacy benefit designs. He will discuss the increasing pressure payers are putting on their PBMs, how PBMs are shifting their business practices to demonstrate value, and what value means to their clients. The following are a few of the key topics that will be addressed:
|